THIS MATERIAL IS A MARKETING COMMUNICATION.
Immunotherapy: a New Approach of Cancer Treatment
Immunotherapy is a type of oncology treatment that helps the immune system fight cancer. The immune system helps the body fight infections and other diseases. Immunotherapy is a type of biological therapy. Biological therapy is a type of treatment that uses substances made of living organisms to treat cancer.
Immuno-oncology therapy, including checkpoint inhibitors, therapeutic cancer vaccines, cytokines and cell therapies, has revolutionized cancer treatment in the past few years. There is still significant room for improvement in immuno-oncology therapy’s efficacy and safety. Continued research and development efforts are underway around the world, with a focus on characterizing novel immuno-oncology targets and exploring combination therapies.
Given the substantial number of cancer patient population in China and the US, the global market size for immuno-oncology therapies is projected to continue growth at a substantial rate both domestically in China and abroad.
Several types of immunotherapy are used to treat cancer. These include:
- Immune checkpoint inhibitors, which are drugs that block immune checkpoints. These checkpoints are a normal part of the immune system and keep immune responses from becoming too strong. By blocking them, these drugs allow immune cells to respond more powerfully against cancer.
- T-cell transfer therapy, which is a treatment that boosts the natural ability of T cells to fight cancer. Those that are most active against cancer are selected or modified in the lab to better attack cancer cells.
- Monoclonal antibodies, which are immune system proteins created in the lab, are designed to bind to specific targets on cancer cells. Some monoclonal antibodies mark cancer cells so that they can be better identified and destroyed by the immune system.
- Treatment vaccines, which work against cancer by boosting the immune system’s response to cancer cells. Treatment vaccines are different from the ones that help prevent disease.
- Immune system modulators, enhance the body’s immune response against cancer. Some of these agents affect specific parts of the immune system, whereas others affect the immune system in a more general way.
The most widely prescribed and efficacious single-agent immuno-oncology antibody therapies that have been discovered and successfully developed to date are PD-(L)1 (programmed cell death protein 1 and programmed death-ligand 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) monoclonal antibodies. In addition to PD-(L)1 and CTLA-4, there are also a number of other immune checkpoints that are being explored in clinical trials.
In this publication, we will discuss PD1 (programmed cell death protein 1) and PDL1s (programmed death-ligand 1) immunotherapy.
TCR - T-cell receptors, APC - antigen-presenting cells, MHC - major histocompatibility complex, Ag – antigens,
Mechanism of Action MOA
PD-1 is a protein located on the surface of T-cells and is one of the proteins commonly referred to as an “immune checkpoint”. The general function of PD-1 is to prevent the T-cell mediated immune response from attacking normal cells in the body when certain proteins called PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2) on the surface of a normal cell bind to it.
Some cancer cells can express high levels of PD-L1 and PD-L2 to bind to the PD-1 on T-cells and thereby help the cancer cells evade T-cell attacks. PD-(L)1 antibody bind to PD-1 or PD-L1 and blocks PD-1 from binding to PD-L1 and/or PD-L2. This prevents the PD-1 found on T-cells from binding with the PD-L1 and/or PD-L2 found on cancer cells, which allows the T-cells to kill the cancer cells.
Immunotherapy has demonstrated success in some cancer types, such as Hodgkin’s lymphoma where the response rate is in the 80-90% range, the average response to anti-PD-(L)1 blockade is only around 15-20% in an all-comer population. (CLSA, 10 December 2019) Many solid tumors have low response rates, including some of the high incidences: gastric, head and neck squamous cell carcinoma, hepatocellular carcinoma, ovarian, cervical, biliary tract, esophageal, triple-negative breast cancer, and Non-Small Cell Lung Cancer – Non-Squamous (“NSCLC”), as shown in the below figure.
ORR – Overall Response Rate. Source: CLSA, British Journal of Cancer, 10th Dec 2019. MCC - Merkel cell carcinoma, Skin SCC – Skin squamous cell carcinoma, DLBCL - Diffuse large B-cell lymphoma, RCC - Renal cell carcinoma, SCLC - small cell lung cancer, NSCLC - Nonsmall-cell lung carcinoma, TNBC - Triple-negative breast cancer, HCC - Hepatocellular carcinoma, HNSCC - Head and neck squamous cell carcinoma, ER+ BC - Estrogen receptor Positive Breast Cancer
Globally, there are currently three PD-1 mAbs (monoclonal antibodies) approved by the US-FDA (US Food and Drug Administration) for 17 cancer indications, and three PD-L1 mAbs for six approved cancer indications. In China, there are currently six PD-1 mAbs and one PD-L1 mAb approved by NMPA(National Medical Products Administration). (Source: Akeso Inc IPO prospectus, April 2020).
PD1 is becoming the cornerstone of treatment - Example of stage IV NSCLC (Non-Small Cell Lung Cancer – Non-Squamous)
Of all types, lung cancer is the largest oncological indication, with 2.09 million patients per year globally, in 2018. (CLSA, 30 June 2020)_
Globally, PD1 is now considered a standard of care for late stage NSCLC (for patients without any driver gene mutations). As seen in the below chart, if patients have actionable drivers, they are typically given targeted, small-molecule therapies, while among patients without actionable driver mutations (those responsive to targeted therapies), the cornerstone treatment is Keytruda (pembrolizumab1) based programs.
There is growing recognition in the academic and industry community that immuno-oncology combination therapies that simultaneously employ different mechanisms of action often display improvement in response rate and durability as compared to single-agent immunotherapies. Therefore, we believe that immuno-oncology combination therapies, especially combinations of two or more targeted therapies, are expected to be one of the future trends of oncology therapies.
With clinical evidence of synergy between PD-(L)1 agents and CTLA-4 agents, PD-(L)1 and CTLA-4 combination therapy has in recent years generated tremendous interests from the pharmaceutical industry. Examples of combination therapies include:
- Dual T Checkpoint Inhibitors, eg. PD-1 or PD-L1 together with, CTLA-4, LAG-3 (Lymphocyte-activation gene 3), TIM-3 (T-cell immunoglobulin and mucin domain-3)
- Checkpoint Inhibitors + Costimulatory Receptor Agonists
- Costimulatory Receptor Agonists + Immunomodulators
- Checkpoint Inhibitors + Target Therapy, eg. VEGFR (vascular endothelial growth factor)
- Checkpoint Inhibitors + Immunomodulators/suppressor
- Checkpoint inhibitors + Other Immune System Activators, eg. chemo, IL-2 (Interleukin-2), Vaccines
As immune checkpoint inhibitors become the standard-of-care in many indications, such as lung cancer, more and more patients are progressing through these therapies, creating the need for treatment beyond PD-1/PDL1s.
There are several links in the immune cancer cycle that offer potential targets for immune-therapy. PD-1 agents target the last step, the killing of cancer cells, while CTLA-4 class of agents target priming and activation.
Staying Ahead with Mirae Asset’s Latest Insights
Disclaimer & Information for Investors
No distribution, solicitation or advice: This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service.
The views and information discussed or referred in this document are as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. In addition, the opinions expressed may differ from those of other Mirae Asset Global Investments’ investment professionals.
Investment involves risk: Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.
Sources: Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (“MAGI”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.
Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGI as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Information for EU investors pursuant to Regulation (EU) 2019/1156: This document is a marketing communication and is intended for Professional Investors only. A Prospectus is available for the Mirae Asset Global Discovery Fund (the “Company”) a société d'investissement à capital variable (SICAV) domiciled in Luxembourg structured as an umbrella with a number of sub-funds. Key Investor Information Documents (“KIIDs”) are available for each share class of each of the sub-funds of the Company.
The Company’s Prospectus and the KIIDs can be obtained from www.am.miraeasset.eu/fund-literature . The Prospectus is available in English, French, German, and Danish, while the KIIDs are available in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the “UCITS Directive”). Please refer to the Prospectus and the KIID before making any final investment decisions.
A summary of investor rights is available in English from www.am.miraeasset.eu/investor-rights-summary/.
The sub-funds of the Company are currently notified for marketing into a number of EU Member States under the UCITS Directive. FundRock Management Company can terminate such notifications for any share class and/or sub-fund of the Company at any time using the process contained in Article 93a of the UCITS Directive.
Hong Kong: It is intended is for Hong Kong investors. Before making any investment decision to invest in the Fund, Investors should read the Fund’s Prospectus and the information for Hong Kong investors (of applicable) of the Fund for details and the risk factors. The individual and Mirae Asset Global Investments (Hong Kong) Limited may hold the individual securities mentioned. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Singapore: It is not intended for general public distribution. The investment is designed for Institutional investors and/or Accredited Investors as defined under the Securities and Futures Act of Singapore. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Monetary Authority of Singapore. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.
Australia: The information contained in this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempted from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. The contents of this document is prepared by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission.
Swiss investors: This document is intended for Professional Investors only. This is an advertising document. The Swiss Representative is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen. The Swiss Paying Agent is Tellco AG, Bahnhofstrasse 4, CH-6431 Schwyz. The Prospectus and the Supplements of the Funds, the KIIDs, the Memorandum and Articles of Association as well as the annual and interim reports of the Company are available free of charge from the Swiss Representative.
UK investors: This document is intended for Professional Investors only. The Company is a Luxembourg registered UCITS, recognised in the UK under section 264 of the Financial Services and Markets Act 2000. Compensation from the UK Financial Services Compensation Scheme will not be available in respect of the Fund. The taxation position affecting UK investors is outlined in the Prospectus. This document has been approved for issue in the United Kingdom by Mirae Asset Global Investments (UK) Ltd, a company incorporated in England & Wales with registered number 06044802, and having its registered office at 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom. Mirae Asset Global Investments (UK) Ltd. is authorised and regulated by the Financial Conduct Authority with firm reference number 467535.
Copyright 2023. All rights reserved. No part of this document may be reproduced in any form, or referred to in any other publication, without express written permission of Mirae Asset Global Investments (Hong Kong) Limited.